|
FOXO3B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.52060000041732E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.0118999999319E-07 |
| Normal-vs-Stage2 |
1.35950000146323E-08 |
| Normal-vs-Stage3 |
4.50570003529549E-09 |
| Normal-vs-Stage4 |
6.98130000476027E-08 |
| Stage1-vs-Stage2 |
7.958100E-02 |
| Stage1-vs-Stage3 |
3.167700E-02 |
| Stage1-vs-Stage4 |
3.497800E-01 |
| Stage2-vs-Stage3 |
8.460800E-01 |
| Stage2-vs-Stage4 |
4.483200E-01 |
| Stage3-vs-Stage4 |
4.880600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.39170000365863E-08 |
| Normal-vs-AfricanAmerican |
1.965810E-02 |
| Normal-vs-Asian |
1.02120000011752E-07 |
| Caucasian-vs-AfricanAmerican |
1.230110E-02 |
| Caucasian-vs-Asian |
7.872600E-01 |
| AfricanAmerican-vs-Asian |
3.827600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.92169999913006E-08 |
| Normal-vs-Female |
5.59089999851992E-08 |
| Male-vs-Female |
4.044200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.90720000026579E-07 |
| Normal-vs-Age(41-60Yrs) |
2.80070000524546E-08 |
| Normal-vs-Age(61-80Yrs) |
3.18409998367741E-09 |
| Normal-vs-Age(81-100Yrs) |
6.22089999999798E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.221190E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.338400E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.823400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.386600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.477400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.376000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.773510E-04 |
| Classical-VS-Follicular |
1.833070E-04 |
| Classical-VS-Other |
8.083200E-01 |
| Classical-VS-Normal |
9.54240000017315E-07 |
| Tall-VS-Follicular |
6.919400E-01 |
| Tall-VS-Other |
3.542400E-01 |
| Tall-VS-Normal |
8.08410005603832E-10 |
| Follicular-VS-Other |
2.883200E-01 |
| Follicular-VS-Normal |
1.12359999082656E-09 |
| Other-VS-Normal |
3.356200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.92219995265708E-09 |
| Normal-vs-N1 |
8.11589999982765E-07 |
| N0-vs-N1 |
4.245600E-01 |
|
|
